First‐line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas

2010761 citationsJournal Articlebronze Open Access

Authors

Jonathan Strosberg · In-Q-Tel

Robert L. Fine · Columbia University Irving Medical Center

Junsung Choi · Moffitt Cancer Center

Aejaz Nasir · Moffitt Cancer Center

Domenico Coppola · Moffitt Cancer Center

Dung‐Tsa Chen · Moffitt Cancer Center

James F. Helm ·

Abstract

The combination of capecitabine and temozolomide is associated with an exceptionally high and durable response rate in metastatic endocrine carcinomas of the pancreas. Clinical endpoints, including response rate, survival, and toxicity, are superior to those observed with streptozocin-based regimens.

Topics & Keywords

Neuroendocrine Tumor Research Advances Pancreatic and Hepatic Oncology Research Neuroblastoma Research and Treatments

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Cancer

Volume 117, Issue 2, pp. 268-275

DOI: 10.1002/cncr.25425

Field-Weighted Citation Impact: 32.60